Procter & Gamble Health Ltd Q1 FY27 Earnings Analysis
Published 30 Jun 2026 | Pharmaceuticals & Biotechnology | Market Cap: ₹8.7K Cr
Price
₹6,326
Market Cap
₹8.7K Cr
P/E Ratio
29.5
Revenue Rank
Margin Rank
Earnings Summary
- Confident of continuing the growth momentum driven by Integrated Growth Strategy focusing on Superiority, Productivity, Constructive Disruption, and Organization. - The company is confident in sustaining and continuing its growth momentum driven by investments in product superiority, innovation, and productivity.
📊 Revenue & Sales Performance
Rank 3- →Confident of continuing the growth momentum driven by Integrated Growth Strategy focusing on Superiority, Productivity, Constructive Disruption, and Organization.
- →Expect balanced growth through strong brand fundamentals, superior retail execution, new user acquisition, and product innovations.
- →Recorded mid-single digit volume growth in FY26, with innovations contributing early single-digit points of growth.
- →Poised for sustained double-digit sales growth, supported by increasing health consciousness and expanding VMS market in India.
- →Export business showing strong potential with 3X growth in Nepal and high single-digit growth in Sri Lanka, adding to overall growth prospects.
- →E-commerce channel rapidly growing and material, contributing to sales growth alongside traditional retail.
- →Management optimistic about combining domestic sales and exports to achieve approximately 15% sales growth over next 5 years.
- →Focus on superior product offerings and expanding reach via enhanced distribution to maintain growth trajectory.
📈 Profitability & Margins
Rank 3- →The company is confident in sustaining and continuing its growth momentum driven by investments in product superiority, innovation, and productivity.
- →Over the next 3-5 years, management aspires to achieve continued sales growth with balanced top-line and bottom-line expansion.
- →Focus remains on delivering sustainable volume growth faster than the industry, supported by strong brand fundamentals and superior retail execution.
- →Recent PAT growth was 30% with a 16% sales increase; a similar growth trajectory is expected via new product launches and deeper market penetration.
- →EBITDA margins are expected to remain healthy due to ongoing productivity efforts, with structural efficiency savings aiding margin expansion.
- →Earnings growth is rooted in the Integrated Growth Strategy pillars: Superiority, Productivity, Constructive Disruption, and Organization engagement.
- →While specific forward-looking numbers are not shared, the company aims for double-digit revenue growth and robust earnings with effective cost management.
🏗️ Capital Expenditure Plans
Yes💰 Fundraising & Capital Structure
No information📋 Order Book & Pipeline
YesKey Metrics
Revenue
Margin
Capex
Fundraise
Order Book
Frequently Asked Questions
What were Procter & Gamble Health Ltd Q1 FY27 results?
- Confident of continuing the growth momentum driven by Integrated Growth Strategy focusing on Superiority, Productivity, Constructive Disruption, and Organization. - The company is confident in sustaining and continuing its growth momentum driven by investments in product superiority, innovation, and productivity.
What is Procter & Gamble Health Ltd share price analysis?
Procter & Gamble Health Ltd currently shows a below-average growth signal. The stock trades at a P/E of 29.5 with a market cap of ₹8,660. Investors should review the full earnings analysis for detailed insights.
Is Procter & Gamble Health Ltd planning capital expenditure?
The document does not explicitly mention any specific current or future capex, capital investment, or strategic investment figures or plans.
This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.
